Correlation Between Glycolytic Phenotype and Tumor Grade in Soft-Tissue Sarcomas by 18F-FDG PET
Open Access
- 21 July 2010
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 51 (8), 1174-1181
- https://doi.org/10.2967/jnumed.109.074229
Abstract
Tumor glycolytic phenotyping can be accomplished with 18F-FDG PET. Tumor 18F-FDG uptake correlates with tumor grade in several cancers. However, the role of 18F-FDG PET for the grading of soft-tissue sarcomas (STSs) warrants further research. Methods: One hundred two patients (48 men and 54 women; mean age ± SD, 50 ± 17 y) with 12 STS subtypes underwent 18F-FDG PET/CT before treatment. Tumor 18F-FDG uptake, expressed as maximum standardized uptake value (SUVmax), was compared among subtypes and correlated with histopathologic grade. Two frequently used sarcoma grading systems—the 3-tier system of the French Federation of Cancer Centers Sarcoma Group (Fédération Nationale des Centres de Lutte Contre le Cancer [FNCLCC]) and a 2-tier system (low grade vs. high grade)—were used. Results: More than 90% of STSs (93/102) exhibited a strong glycolytic phenotype (SUVmax, 2.7–52.2 g/mL). Tumor SUVmax differed significantly among tumor grades (P < 0.001 for the 3- and 2-tier grading systems). The FNCLCC and 2-tier grading systems predicted tumor grade with similar accuracy (area under the curve, 0.83 and 0.85, respectively; P = 0.35). SUVmax differed significantly among histologic subtypes (P = 0.03) in the entire population but not when high-grade STSs were analyzed separately (P = 0.31). Conclusion: The tumor glycolytic phenotype correlated significantly with histologic grade as determined by both the FNCLCC and 2-tier (high vs. low) grading systems. 18F-FDG PET cannot be used to reliably distinguish among grade 2 and 3 STSs (by FNCLCC) and the various subtypes.This publication has 40 references indexed in Scilit:
- Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benignCancer, 2009
- Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristicsNuclear Medicine Communications, 2009
- FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue SarcomasClinical Cancer Research, 2009
- Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding TumorsJournal of Nuclear Medicine, 2008
- Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]FluorodeoxythymidineClinical Cancer Research, 2008
- Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue SarcomasClinical Cancer Research, 2008
- Intensity of18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2005
- Core-needle biopsy performed by the cytopathologistCancer, 2005
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysisCancer Treatment Reviews, 2004